- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Malignant melanoma Non-Small Cell Lung Cancer (NSCLC). Renal Cell Carcinoma (RCC). Squamous Cell Carcinoma of the Head and Neck (SCCHN). Urothelial Carcinoma (UC). Oesophageal / Gastro-oesophageal cancers(OC/GC).
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Nivolumab – March 2026
Solution for subcutaneous injection 600 mg in 5 mL,
Last updated
11 March 2026